Cardax

Cardax, Inc. is a development stage biopharmaceutical company, which engages in development of pharmaceuticals for chronic diseases driven by inflammation. The company is headquartered in Honolulu, Hawaii and currently employs 10 full-time employees. The company went IPO on 2012-01-30. The firm markets ZanthoSyn, an astaxanthin dietary supplement for lifespan and health span (inflammatory health), including joint and muscle function, cognitive performance, and cardiovascular health. ZanthoSyn is available through its commercial Website. ZanthoSyn contains pure astaxanthin prepared by natural product total synthesis. The firm is also advancing CDX-101, its pharmaceutical candidate, for the diseases of aging. CDX-101 is an astaxanthin Rx candidate for cardiovascular inflammation and dyslipidemia. CDX-301 is its zeaxanthin pharmaceutical candidate for macular degeneration. The company may seek to monetize its CDX-301 pharmaceutical assets through licensing or sale.